Roche's Setback: Giredestrant Fails in Key Breast Cancer Trial

Roche's stock dropped over 5% as its drug giredestrant failed in a trial for breast cancer. The phase III trial didn't show significant progression delay when combined with Pfizer's Ibrance compared to standard hormonal therapy. This setback marks a reverse in the drug's promising trajectory.

Shares in Roche tumbled Monday, dropping more than 5%, as the Swiss pharmaceutical giant faced disappointment with its breast cancer drug candidate, giredestrant. The decline came after a phase III trial failed to show that the drug, when used with Pfizer's Ibrance, significantly slowed disease progression compared to standard hormonal therapy.

Previously celebrated for reducing the risk of tumor recurrence in a late-stage trial, giredestrant, classified as an oral selective oestrogen receptor degrader (SERD), is now under scrutiny following this setback. The compound was seen as a promising treatment for a common form of breast cancer that accounts for up to 80% of cases.

The competitive landscape for SERDs includes AstraZeneca's camizestrant, which is also in development. The market potential remains significant, but Roche must now reassess its strategy as a reversal in fortunes impacts its shares negatively.

(With inputs from agencies.)